Skip to main content
. 2016 Apr 15;27(8):1220–1234. doi: 10.1091/mbc.E15-08-0557

FIGURE 6:

FIGURE 6:

Atorvastatin is synthetically lethal with trappc11 mutation. (A) Transgenic WT and trappc11-mutant embryos expressing a liver-specific marker (Tg(fabp10:dsRed)) were treated with DMSO or the HMG-CoA reductase inhibitor, Atv, between 3 and 5 dpf at the concentrations indicated and analyzed for gross morphology and lethality. (B) Livers were collected from WT (n = 7 clutches), trappc11 (n = 8 clutches), and 5 μM Atv–treated WT embryos between 3 and 5 dpf (n = 7 clutches) and subjected to qPCR to analyze UPR gene expression used to calculate PC1. p values were calculated with Student’s t test. n.s., not significant. (C) Livers from larvae treated with DMSO or 1 μM Atv from 3 to 5 dpf (n = 8 clutches) were collected and analyzed at 5 dpf for the expression of genes involved in N-linked glycosylation. Atorvastatin-induced fold increases are shown relative to DMSO-treated samples.